In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates

Journal of Chemotherapy

Volumn 24, Issue 5, 2012, Pages 247-252

  Deveci, Aydin ^a   Coban, Ahmet Yilmaz ^b   Acicbe, Ozlem ^a   Tanyel, Esra ^a   Yaman, Gorkem ^c   Durupinar, Belma ^b  

^a Department of Infectious Diseases and Clinical Microbiology ^*  (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^c YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

A. baumannii; MDR; Sulbactam; Synergy

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; MEROPENEM; SULBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG CONCENTRATION; DRUG EFFECT; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COLISTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; GENTAMICINS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SULBACTAM; THIENAMYCINS;

EID: 84866670831     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000029     Document Type: Article

References (29)

1. Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian VL. editor. Antibiotics in laboratory medicine. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins 2005 n. 365-424
2. Moody J. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: Isenberg HD, editor. Clinical microbiology procedures handbook. 2nd ed. Washington (DC): ASM Press; 2004. p. 1-28.
3. Falagas ME, Karveli EA. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infect. 2007;13(2): 117-9.
4. Neonakisn IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents. 2011;37(2):102-9.
5. Gilad J, Carmeli Y. Treatment options for multidrug-resistant Acinetobacter species. Drugs. 2008;68(2):165-89.
6. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect. 2007;13(2):196-8.
7. Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother. 2010;11(5):779-88.
8. Kiffer CR, Sampaio JL, Sinto S, Oplustil CP, Koga PC, Arruda AC, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2005:52(4):317-22.
9. Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother. 2004:53(2):393-5.
10. Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy. 2007:27(11):1506-11.
11. Wang FD, Lin ML, Lee WS, Liu CY. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria. Int J Antimicrob Agents. 2004:23(6): 590-5.
12. Aubert G, Guichard D, Vedel G. In-vitro activity of cephalo-sporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. J Antimicrob Chemother. 1996:37(1):155-60.
13. Fuchs PC, Stickel S, Anderson PH, Barry AL, Shilling S. In vitro inactivation of aminoglycosides by sulbactam, other-β-lactams, and sulbactam- β-lactam combinations. Antimicrob Agents Chemother. 1991:35(1):182-4.
14. Savov E, Chankova D, Vatcheva R, Dinev N. In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin. Int J Antimicrob Agents. 2002:20(5):390-2.
15. Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM. Synergistic activity of sulbactam combined with colistin against colistin resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012:39(2):180-1.
16. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 2006;57(3):573-6.
17. Kiratisin P, Apisarnthanarak A, Kaewdaeng S. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents. 2010;36(3):243-6.
18. Frimodt-Moller N. How predictive is PK/PD for antibacterial agents. Int J Antimicrob Agents. 2002;19(4):333-9.
19. Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharma. 2009;66(12 Suppl 4):S23-30.
20. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiol-ogy, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254-63.
21. Dizbay M, Tunccan OG, Sezer BE, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epide-miology and risk factors. Scand J Infect Dis. 2010;42(10):741-6.
22. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and manage-ment. Curr Opin Infect Dis. 2010;23(4):332-9.
23. Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect. 2009;73(4):355-63.
24. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanism of virulance and resistance. Int J Antimicrob Agents. 2010;35(3):219-26.
25. Coyne S, Courvalin P, Perichon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother. 2011;55(3):947-53.
26. Vila J, Pachon J. Acinetobacter baumannii resistant to everything: what should we do? Clin Microbiol Infect. 2011;17(7):955-6.
27. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenemresistant Acinetobacter spp. J Antimicrob Chemother. 2008;61(6):1369-75.
28. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A6, 6th ed., Wayne (PA): CLSI; 2003.
29. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, twenty-second informational supplement. M100-S22, Wayne (PA): CLSI; 2012